8-K: Heron Therapeutics Reports Q2 2024 Results, Narrows Financial Guidance

Heron Therapeutics announced its second quarter 2024 financial results, highlighted by increased product sales and narrowed financial guidance.

Summary

• Heron Therapeutics reported a net product sales increase to $36.0 million for the second quarter of 2024, up from $31.8 million in the same period of 2023.
• The company has narrowed its full-year 2024 adjusted operating expenses guidance to a range of $107.0 million to $111.0 million, down from the previous range of $108.0 million to $116.0 million.
• Adjusted EBITDA guidance for 2024 has also been narrowed to a range of $(10.0) million to $3.0 million, compared to the previous range of $(22.0) million to $3.0 million.
• ZYNRELEF net product sales were $5.8 million for the quarter and $10.8 million for the six months ended June 30, 2024, up from $4.2 million and $7.7 million respectively in 2023.
• APONVIE net product sales were $1.0 million for the quarter and $1.5 million for the six months ended June 30, 2024, up from $0.3 million and $0.6 million respectively in 2023.
• CINVANTI net product sales were $24.9 million for the quarter and $50.5 million for the six months ended June 30, 2024, up from $24.5 million and $47.3 million respectively in 2023.
• SUSTOL net product sales were $4.3 million for the quarter and $7.9 million for the six months ended June 30, 2024, up from $2.8 million and $5.8 million respectively in 2023.
• The PDUFA goal date for the ZYNRELEF Vial Access Needle (VAN) is set for September 23, 2024, with an anticipated launch before year-end.
• The company expects to submit an application for the ZYNRELEF Prefilled Syringe (PFS) to the FDA in 2026.
• ZYNRELEF is included in the proposed 2025 Non-Opioid Policy for Pain Relief (NOPAIN Act) and is expected to maintain separate reimbursement in HOPD and ASC settings from April 1, 2025.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with positive revenue growth and narrowed guidance, but also ongoing losses and the need for potential future financing. The sentiment is cautiously optimistic.

Positives

• Net product sales increased year-over-year for both the quarter and six-month period.
• The company is improving financial efficiency by growing revenues, improving margins, and reducing expenses.
• The adjusted operating expenses and adjusted EBITDA guidance ranges have been narrowed, indicating better cost control.
• The ZYNRELEF VAN is progressing towards a launch before the end of the year.
• The inclusion of ZYNRELEF in the proposed 2025 NOPAIN Act is a positive development for reimbursement.
• The training and integration of CrossLink sales representatives is progressing rapidly, which should lead to increased adoption of ZYNRELEF.

Negatives

• The company is still operating at a loss, with a net loss of $9.2 million for the quarter and $12.4 million for the six-month period.
• The company's cash and cash equivalents decreased from $28.7 million at the end of 2023 to $18.4 million as of June 30, 2024.
• The company is still reliant on future equity financings to fund operations.

Risks

• The company's future performance is subject to risks and uncertainties, including market opportunities, regulatory approvals, and commercial arrangements.
• There is a risk that the company may not achieve profitability.
• The company is subject to litigation, including ANDA litigation.
• The company may be required to write-off additional inventory in the future.
• The company's cash reserves are decreasing, and future equity financings may be needed.

Future Outlook

The company anticipates a fourth-quarter launch of the ZYNRELEF VAN and expects to submit an application for the ZYNRELEF PFS to the FDA in 2026. They also expect ZYNRELEF to maintain separate reimbursement under the NOPAIN Act from April 1, 2025.

Management Comments

• Craig Collard, Chief Executive Officer of Heron, stated that the company has had an exciting start to 2024 with many encouraging milestones.
• He also mentioned that they are improving the financial efficiency of the business by growing revenues, improving margins, and reducing expenses.
• He noted the company is progressing regulatory activities in anticipation of a fourth quarter launch of the VAN.

Industry Context

This announcement reflects the ongoing challenges and opportunities in the biotechnology sector, where companies are focused on commercializing innovative therapies while managing costs and navigating regulatory hurdles. The inclusion of ZYNRELEF in the proposed NOPAIN Act is a positive development that could improve market access and reimbursement for the product.

Comparison to Industry Standards

• Heron's revenue growth in Q2 2024 is a positive sign, but the company's continued losses are a concern. Companies like Pacira BioSciences (PCRX) and Flexion Therapeutics (FLXN), which also focus on pain management, have shown varying levels of profitability and revenue growth.
• Pacira BioSciences, for example, has a more established product portfolio and has achieved profitability, while Flexion Therapeutics has faced challenges in commercializing its products. Heron's performance is somewhere in between, showing growth but still needing to achieve profitability.
• The successful launch of the ZYNRELEF VAN and the inclusion of ZYNRELEF in the NOPAIN Act could be significant catalysts for future growth, but the company needs to manage its expenses and cash flow effectively to achieve long-term success.
• Compared to other biotech companies in the commercialization stage, Heron's focus on both acute care and oncology products provides diversification, but also requires significant investment in sales and marketing.

Legal Proceedings

• The company is involved in pending ANDA litigation.

Stakeholder Impact

• Shareholders will be impacted by the financial results and future outlook.
• Employees will be impacted by the company's financial performance and strategic direction.
• Customers (healthcare providers and patients) will be impacted by the availability and reimbursement of the company's products.
• Suppliers and creditors will be impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• The company will continue to progress the development of the ZYNRELEF VAN and PFS.
• They will focus on the commercial launch of the ZYNRELEF VAN.
• They will continue to integrate and train CrossLink sales representatives.
• They will monitor the progress of the proposed 2025 NOPAIN Act.
• They will host a conference call and webcast on August 6, 2024, to discuss the results.

Key Dates

Keywords

ZYNRELEF, APONVIE, CINVANTI, SUSTOL, Net Product Sales, EBITDA, Operating Expenses, PDUFA, NOPAIN Act, FDA, Biotechnology, Pharmaceuticals